Optimizing antimicrobial treatment schedules: some fundamental analytical results

Guy Katriel

Department of Applied Mathematics, Braude College of Engineering, Karmiel, Israel.

Contributing authors: katriel@braude.ac.il;

Abstract

This work studies fundamental questions regarding the optimal design of antimicrobial treatment protocols, using pharmacodynamic and pharmacokinetic mathematical models. We consider the problem of designing an antimicrobial treatment schedule to achieve eradication of a microbial infection, while minimizing the area under the time-concentration curve (AUC), which is equivalent to minimizing the cumulative dosage. We first solve this problem under the assumption that an arbitrary antimicrobial concentration profile may be chosen, and prove that the *ideal* concentration profile consists of a constant concentration over a finite time duration, where explicit expressions for the optimal concentration and the time duration are given in terms of the pharmacodynamic parameters. Since antimicrobial concentration profiles are induced by a dosing schedule and the antimicrobial pharmacokinetics, the 'ideal' concentration profile is not strictly feasible. We therefore also investigate the possibility of achieving outcomes which are close to those provided by the 'ideal' concentration profile, using a bolus+continuous dosing schedule, which consists of a loading dose followed by infusion of the antimicrobial at a constant rate. We explicitly find the optimal bolus+continuous dosing schedule, and show that, for realistic parameter ranges, this schedule achieves results which are nearly as efficient as those attained by the 'ideal' concentration profile. The optimality results obtained here provide a baseline and reference point for comparison and evaluation of antimicrobial treatment plans.

Keywords: Antimicrobial treatment, Mathematical models, Pharmacokinetics, Pharmacodynamics, Optimization

1 Introduction

Antimicrobial agents have made an immense contribution to human welfare, and their effective and efficient use is an issue of crucial importance (Owens et al. (2004), Rotschafer et al. (2016)), particularly in view of the global antimicrobial resistance crisis, which is driven, in part, by mis-use or over-use (Murray et al. (2022), Ventola (2015)). Mathematical modelling plays an important role in exploring the dynamics of microbial growth, antimicrobial pharmacokinetics (the absorption, distribution and elimination of the drug in the body) and pharmacodynamics (the drug's effect on the microbial population) (Nielsen and Friberg (2013), Vinks et al. (2014)). Coupled with experimental laboratory work and clinical studies, mathematical modelling aids in the design and evaluation of treatment protocols and guidelines (Bulitta et al. (2019), Rayner et al. (2021), Rao and Landersdorfer (2021)).

A traditional and widely-employed approach to the quantitative design of antimicrobial treatment regimens employs several PK/PD indices which quantify exposure over a time period, and uses experimental studies to determine the index which is maximally correlated to measures of efficacy for a particular antimicrobial, with respect to a specific microbial species (Onufrak et al. (2016), Owens et al. (2004), Vinks et al. (2014)). A different methodology, known as 'mechanism-based' or 'semi-mechanistic' modelling (Bouvier d'Yvoire and Maire (1996), Czock and Keller (2007), Mi et al. (2022), Mueller et al. (2004), Nielsen and Friberg (2013), Rao and Landersdorfer (2021)) relies on modelling the full time-course of treatment using dynamic models which describe the time dependence of both the microbial population and the antimicrobial agent's concentration, most often using differential equations. Such models include both pharmacokinetic parameters, related to drug distribution and elimination, and pharmacodynamic parameters, related to antimicrobial effect on the microbial population, and these parameters are estimated by fitting models to experimental data (Bhagunde et al. (2015), Czock and Keller (2007), Kesisoglou et al (2022), Mouton and Vinks (2005), Nielsen and Friberg (2013), Regoes et al. (2004), Wen et al. (2016)). Once such a model is calibrated and validated, it can serve as an *in-silico* experimental system, allowing to test the outcomes of a variety of treatment schedules.

Alongside the development of relevant mathematical models, a variety analytical tools have been developed in order to gain understanding of the dynamic behavior of PK/PD models, and of how the parameters involved affect the outcomes of treatment (Krzyzanski and Jusko (1998), Machera and Iliadis (2016), Mudassar and Smith (2005), Nguyen and Peletier (2009), Peletier et al. (2005), Rescigno (2003), Wu et al. (2022)).

The availability of mechanism-based models raises the prospect of systematic determination of *optimal* treatment plans, using mathematical and computational approaches, and indeed several researchers have undertaken such investigations. The dynamical models used, as well as the class of candidate treatment schedules considered and the quantities targeted for optimization, vary among different works. Computationally intensive methods are used for the purpose of finding the optimal schedules, including optimal control methods (Ali et al. (2022), Khan and Imran

(2018), Peña-Miller et al. (2012), Zilonova et al. (2016)), genetic algorithms (Cicchese et al. (2017), Colin et al. (2020), Goranova et al. (2022), Hoyle et al. (2020), Paterson et al. (2016)) and machine learning (Smith et al. (2020)). While such computational work is very valuable and has the advantage of enabling the study of relatively elaborate models, it is also important to approach antimicrobial treatment optimization from an analytical point of view, with the aim of obtaining general insights and mathematical results.

By employing simple, but widely used, mathematical models, and by formulating natural optimization problems, we can mathematically prove several general results characterizing optimal treatment plans. An analytic approach provides generic results which are valid for *all* parameter values of a model, rather than for specific sets of parameters as in numerical studies, and enables to obtain useful explicit formulas for determining the quantitites characterizing the optimal treatment regimens. The results yield fundamental understanding of the problem of optimal treatment with an antimicrobial agent. To the extent that the (standard) mathematical models used here capture the dynamics of microbial growth and the effect of antimicrobials, the results offer practical guidelines for the design of antimicrobial treatment schedules, as will be discussed.

We now provide an overview of the contributions presented in this work, referring to the corresponding sections for details.

We formulate and address some key issues regarding optimal antimicrobial treatment. Stated simply (and to be formulated more precisely below), our question is:

Given that we aim to use an antimicrobial agent to eradicate a microbial infection, what is the treatment plan that will do so using a minimal cumulative dosage of antimicrobial?

The essential tradeoff underlying this optimization problem is that, while a low concentration of antimicrobial will be insufficient to suppress microbial growth, a very high concentration will be wasteful due to the saturation of the antimicrobial effect at high concentrations, as well as increase the risk of toxicity. To quantitatively illuminate this tradeoff, we use a standard pharmacodynamic model describing the growth of a microbial population and a killing rate of microbes depending on the antimicrobial concentration, see section 2. In the context of such a model, the microbial population size cannot reach 0, so that 'eradication' is defined in terms of reducing the microbial population size by a given factor, which will depend on the initial microbial population size.

Our work consists of two parts, in which we address the above question on two levels. In our first investigation (sections 3-4) we allow an arbitrary time-dependence of the antimicrobial concentration at the infection site, and seek to find, among those concentration profiles which lead to eradication of the microbial population, the one for which the area under the time-concentration curve (AUC) is minimal. The AUC is a standard measure for the overall exposure (Nielsen and Friberg (2013)), and indeed it is proportional to the cumulative antimicrobial dosage (see equation (5.3)). In this formulation of the problem, we are focusing on the pharmacodynamics, ignoring the

fact that not every concentration profile is *pharamacokinetically feasible*, in the sense that it can be induced by an appropriate dosing schedule - these pharmacokinetic aspects are addressed in the second part of the paper. In this general context, we obtain several results:

- (i) The optimal antimicrobial concentration profile consists of a *constant* concentration c_{opt} applied for a finite time duration T_{opt} .
- (ii) We find an algebraic equation which allows us to determine the values c_{opt} and T_{opt} . In the case that the pharmacodynamics is described by a Hill function (the most commonly employed pharmacodynamic model) we solve this equation to obtain explicit expressions for c_{opt} and T_{opt} in terms of the pharmacodynamic parameters (see section 4).
- (iii) The optimal antimicrobial concentration c_{opt} is independent of the initial size of the microbial population, which only affects the duration T_{opt} of the optimal treatment.

The above results establish a *baseline* in the sense that they provide a lower bound for the AUC needed to achieve eradication. However, this analysis focuses only on the pharamacodynamics, that is the drug effect, ignoring the limitations on the concentration profile induced by pharmacokinetics - the dynamics of drug absorption and elimination. The 'ideal' concentration curve which achieves the lower bound, consisting of a constant concentration value over a finite time-interval, is not strictly achievable in practice, due to the simple fact that drug concentration cannot drop to 0 in a single instant, but rather decays in a gradual way. Therefore, in section 5, we address the question of achieving efficient treatment using drug concentration profiles which are 'pharmacokinetically feasible'. We would like to achieve results which are close to the 'ideal' baseline determined in the first part of this work, but which can be realistically attained by a dosage plan, preferably one that is simple to implement. In this work we restrict ourselves to a simple one-compartment pharmacokinetic model - leaving consideration of more complex pharmacokinetics to future work. The only pharmacokinetic parameter is thus the rate of drug decay. In this context, we examine simple dosage plans of the *bolus+continuous* type (Derendorf and Schmidt (2019)), in which a single (bolus) dose of the antimicrobial is given at the initiation of treatment, in order to instantaneously raise the drug concentration to a level \bar{c} , and constant-rate infusion is provided thereafter, for a time duration T_{bc} , in order to maintain the same concentration. The initial dose and the constant rate of infusion are determined by the desired concentration and the pharmacokinetic parameter (rate of drug decay). This choice of dosing schedule mimicks the 'ideal' concentration profile in that the concentration is constant for a finite duration, but with exponential decay thereafter. Optimizing over all such dosing schedules (that is over all choices of \bar{c} and T_{hc}) which achieve eradication, with the aim of minimizing the AUC (which is equivalent to minimizing cumulative dosage), we find the following:

(i) The optimal concentration \bar{c} is (somewhat surprisingly) identical to the value c_{opt} obtained for the 'ideal' concentration profile in the first part of our work. In particular, it does not depend on the pharamacokinetics, that is on the rate of decay of the antimicrobial.

- (ii) The optimal time duration $T_{bc,opt}$ over which the constant-rate infusion of drug should be performed is given by an explicit formula, and depends both on the pharmacodynamics and on the rate of decay of the antimicrobial. This duration is always shorter than the duration T_{opt} of the 'ideal' concentration profile.
- (iii) If the antimicrobial decay rate is sufficiently small, then $T_{bc} = 0$, that is the optimal bolus+continuous schedule consists only of a bolus dose, and if the antimicrobial decay rate is large, then T_{bc} is close to T_{opt} , and the AUC corresponding to the optimal bolus+continuous treatment is close to (though somewhat higher than) the AUC of the 'ideal' concentration profile.

Numerical results given in section 6, computed for the case of a Hill-type pharmacodynamic function, with realistic ranges of values of the pharmacokinetic and pharmacodynamic parameters, show that, in most cases, the optimal bolus+continuous dosing schedule achieves results which are nearly as efficient as those attained using the 'ideal' concentration profile, in that the AUC valued attained is not significantly higher. We thus conclude that a bolus+continuous dosing schedule, suitably designed, provides a nearly-optimal solution under many circumstances. We also include a brief discussion and demonstration of the possibility of approximating a bolus+continuous dosing schedule by an intermittent schedule consisting of a series of bolus doses.

While the results obtained here provide what we believe to be an essential theoretical basis for thinking about the optimization of antimicrobial treatments, there are various complicating issues that should be taken into account in considering the application of these results in concrete settings. In section 7 we address some of the limitations of the standard modelling framework employed in this work, and suggest directions for further investigation.

2 The pharmacodynamic model

In this section we describe the modelling framwork which will be employed to study antimicrobial treatment schedules, which is standard in the field of pharmacodynamics (Austin et al. (1998), Bhagunde et al. (2015), Bouvier d'Yvoire and Maire (1996), Corvaisier et al. (1998), Goranova et al. (2022), Hoyle et al. (2020), Kesisoglou et al (2022), Mouton and Vinks (2005), Nielsen and Friberg (2013), Nikolaou and Tam (2006), Nikolaou et al. (2007)). The notation to be used is summarized in Table 1.

An antimicrobial treatment schedule will determine a function C(t) $(t \ge 0)$ describing the concentration of antimicrobial at the infection site as a function of time t, which we will call the *concentration profile*. We allow C(t) to be an arbitrary non-negative function in the class $L^1[0,\infty)$ of integrable functions.

The area under the concentration curve

$$AUC = AUC[C(t)] = \int_0^\infty C(t)dt,$$
(2.1)

is a standard measure of the intensity of the antimicrobial treatment. Indeed it may be seen that the AUC is proportional to the cumulative dosage of the antimicrobial supplied, see equation (5.3). Denoting by B(t) the size of the microbial population at time t, we use the standard constant-rate model of microbial growth in the absence of treatment

$$\frac{dB}{dt} = rB,$$

where r is the difference of the replication rate and the natural death rate, leading to exponential growth, with doubling time

$$T_2 = \frac{\ln(2)}{r}.$$
 (2.2)

The antimicrobial effect is modelled using a function k(c), known as the pharmacodynamic function (Regoes et al. (2004)), or the kill curve (Mueller et al. (2004)), which describes the kill-rate of the antimicrobial agent at concentration c. Note that we will be using lower-case c to denote an arbitrary value of antimicrobial concentration, while the upper-case C(t) is used for describing the antimicrobial concentration as a function of time.

In the presence of antimicrobial, the microbial population is thus described by

$$\frac{dB}{dt} = [r - k(C(t))]B, \qquad (2.3)$$

with solution

$$(t) = B_0 \cdot e^{\int_0^t [r - k(C(s))] ds}, \tag{2.4}$$

where B_0 is the initial microbial population size at time t = 0. The kill-rate function k(c) will be assumed to have the following properties

- (A1) k(0) = 0, and k(c) is continuous and monotone increasing on $[0, \infty)$, and twice differentiable for c > 0.
- (A2) The kill rate saturates at high concentrations:

$$\lim_{c \to \infty} k(c) = k_{max} < \infty.$$
(2.5)

(A3) The function k(c) satisfies one of the following two conditions:

B

(i) k(c) is strictly **concave**, that is k''(c) < 0 for all $c \ge 0$. or

(ii) k(c) is **sigmoidal**, that is, there exists a value $c_{infl} > 0$ (the inflection point) so that

$$0 < c < c_{infl} \Rightarrow k''(c) > 0 \text{ and } c > c_{infl} \Rightarrow k''(c) < 0.$$

Example. The most common functional form used for the pharmacodynamic function is the Hill function, also known as the Sigmoid E_{max} model (Meibohm and Derendorf (1997)) or the Zhi model (Corvaisier et al. (1998), Zhi et al. (1988))

$$k_H(c) = k_{max} \cdot \frac{c^{\gamma}}{C_{50}^{\gamma} + c^{\gamma}},\tag{2.6}$$

where $\gamma > 0$ is called the Hill exponent and C_{50} is the half-saturation constant, the concentration at which the kill rate is half of the maximal value k_{max} . In the survey of Czock and Keller (2007) one may find tables with estimates of the parameters C_{50}, k_{max}, γ for various combinations of antimicrobials and microbial species, obtained through many empirical studies.

The function $k_H(c)$ is concave if $\gamma \leq 1$, and sigmoidal if $\gamma > 1$, in which case the inflection point is given by

$$c_{infl} = C_{50} \cdot \left(\frac{\gamma - 1}{\gamma + 1}\right)^{\frac{1}{\gamma}}.$$

Our main results do not depend on this specific functional form, but we will apply the general results to this specific example, and obtain useful explicit expressions - see in particular sections 4 and 6.

It will be useful to introduce the dimensionless parameter

$$\alpha = \frac{k_{max}}{r},\tag{2.7}$$

measuring the maximal kill-rate of the antimicrobial relative to the natural microbial growth rate, which we will therefore call the *potency* of the antimicrobial with respect to a microbial species. We will make the standing assumption that $\alpha > 1$, that is $k_{max} > r$, which means that a sufficiently large concentration will lead to a negative net growth rate of the microbial population - if this is not the case then the antimicrobial is not effective. Under this assumption, and in view of the assumption (A1) above, there exists a unique value of c, denoted by zMIC, the pharmacodynamic minimal inhibitory concentration (Bouvier d'Yvoire and Maire (1996), Corvaisier et al. (1998)), also referred to as the stationary concentration (SC) (Czock and Keller (2007), Mouton and Vinks (2005)), such that

$$k(zMIC) = r. (2.8)$$

Example. In the case that the kill-rate is given by a Hill function (2.6), solving (2.8) for zMIC and using (2.7) gives

$$zMIC = C_{50} \cdot (\alpha - 1)^{-\frac{1}{\gamma}}$$
 (2.9)

Note that within the framework of model (2.3) the microbial population cannot be reduced to 0, since B(t) given by (2.4) is always positive, and indeed if AUC is finite then for large time the microbial population will recover, with $B(t) \to +\infty$ as $t \to \infty$. However, in practice, reaching a sufficiently low value of B(t) at some point in time, *e.g.* corresponding to less than one organism, implies eradication. The appropriate measure for the success of treatment is therefore the *maximal* reduction in the size of the microbial population achieved at some time. The reduction is standardly expressed on a logarithmic scale, by defining the log-reduction at time ${\cal T}$

$$LR(T) = \log_{10}\left(\frac{B_0}{B(T)}\right) = \frac{1}{\ln(10)} \cdot \ln\left(\frac{B_0}{B(T)}\right),$$

(we use base 10 in order to be consistent with the literature) which in view of (2.4) is given by

$$LR(T) = \frac{1}{\ln(10)} \cdot \int_0^T [k(C(t)) - r] dt.$$
(2.10)

The maximal reduction afforded by the concentration profile C(t) is then

$$LR_{max} = LR_{max}[C(t)] = \max_{T \ge 0} LR(T).$$
(2.11)

We note that, since LR(0) = 0 and $\lim_{T\to\infty} LR(T) = -\infty$, the maximum in (2.11) certainly exists.

Eradication of the infection thus corresponds to achieving $LR_{max}[C(t)] \ge LR_{target}$, where the value of LR_{target} is given.

Symbol	Description
B(t)	Microbial population size at time t .
B_0	Initial microbial population size.
C(t)	Antimicrobial concentration at time t .
AUC[C(t)]	Area under the time-concentration curve $C(t)$, see (2.1).
r	Microbial growth rate in absence of antimicrobial.
T_2	Microbial doubling time in absence of antimicrobial, see (2.2) .
k(c)	Kill-rate of antimicrobial, in dependence on its concentration.
k_{max}	Maximal kill-rate of antimicrobial, see (2.5) .
$k_H(c)$	Hill model for kill-rate, see (2.6) .
γ	Hill exponent, see (2.6) .
C_{50}	Half saturation constant for Hill model, see (2.6) .
α	Antimicrobial potency relative to a microbial species, see (2.7) .
c_{infl}	Inflection point of $k(c)$, in the sigmoidal case.
zMIC	Pharmacodynamic minimal inhibitory concentration, see (2.8) .
LR(T)	log (base 10) reduction of microbial population at time T , see (2.10).
$LR_{max}[C(t)]$	Maximal log reduction of microbial population corresponding to a
	given concentration profile, see (2.11) .
LR_{target}	Target log reduction of microbial population for achieving eradica-
	tion.
$C_{opt}(t)$	Optimal antimicrobial concentration profile, see Theorem 1.
c_{opt}	Optimal antimicrobial concentration, see Theorem 1.
T_{opt}	Duration of optimal concentration profile, see (3.4) .
AUC_{opt}	Minimal AUC attainable by any antimicrobial concentration profile
	achieving eradication, given by (3.5) .
LR_{opt}	Maximal log reduction attainable by a concentration profile with
	given AUC , given by (3.6) .

T_{min}	Greatest lower bound for the time to achieve eradication, see (3.17) .
μ	Antimicrobial decay rate.
au	Antimicrobial half-life, see (5.2) .
d(t)	Antimicrobial dosing rate at time t .
$d_{bc}(t)$	bolus+continuous dosing schedule, see (5.5) .
$d_{bc,opt}(t)$	optimal bolus+continuous dosing schedule, see (5.8) .
T_{bc}	Duration of dosing for a bolus+continuous schedule.
$T_{bc,opt}$	Duration of the optimal dosing of bolus+continuous type, see (5.22) .

Table 1: Notation

3 Optimizing treatment: the 'ideal' concentration profile

Our aim is to choose a concentration profile C(t), among all non-negative integrable functions on $[0, \infty)$, so as to minimize the AUC, while achieving a specified log-reduction of the microbial load. We therefore formulate:

Problem 1. Given a target value LR_{target} , find a concentration profile C(t) achieving $LR_{max}[C(t)] = LR_{target}$, where LR_{max} is given by (2.11), with the corresponding AUC (given by (2.1)) as small as possible.

The following theorem provides a complete solution to this problem.

Theorem 1. Assume (A1)-(A3) and $\alpha > 1$. Let a value LR_{target} be given. The unique solution of Problem 1 is given by the concentration profile

$$C_{opt}(t) = \begin{cases} c_{opt} & 0 \le t \le T_{opt} \\ 0 & t > T_{opt} \end{cases},$$
(3.1)

where c_{opt} is the unique maximizer of the function $f_r: (0,\infty) \to \mathbb{R}$ defined by

$$f_r(c) = \frac{k(c) - r}{c},\tag{3.2}$$

which is also the unique solution of the equation

$$k'(c) = \frac{k(c) - r}{c},$$
(3.3)

and

$$T_{opt} = \frac{\ln(10) \cdot LR_{target}}{k(c_{opt}) - r}.$$
(3.4)



Fig. 1 Graphical construction for determining the optimal concentration c_{opt} . Plot the straight line which passes through the point (0, r) and is tangent to the curve k(c). The abscissa at the tangency point is the value c_{opt} . In this plot we use the Hill curve (2.6) with $\gamma = 3$, $C_{50} = 1$, $k_{max} = 1$, and r = 0.4.

The solution $C_{opt}(t)$ leads to eradication at time T_{opt} (that is, $LR(T_{opt}) = LR_{target}$), and achieves the minimal value possible of AUC, given by

$$AUC_{opt} = T_{opt} \cdot c_{opt} = \ln(10) \cdot LR_{target} \cdot \frac{c_{opt}}{k(c_{opt}) - r}.$$
(3.5)

Several notable consequences emerge from Theorem 1:

- (i) The 'ideal' dosing strategy is to keep the concentration of antimicrobial *constant* at c_{opt} for the duration of time determined by T_{opt} .
- (ii) By (3.3), c_{opt} depends only on the microbial growth rate r and on the kill-rate function k(c), and not on the target reduction LR_{target} . Thus the given target reduction affects the optimal schedule only through its effect on the duration T_{opt} , which, by (3.4), depends linearly on LR_{target} .
- (iii) By (3.5), the minimal achievable AUC depends linearly on the target reduction LR_{target} .

We note that equation (3.3) leads to a graphical construction for obtaining the optimal concentration c_{opt} - see Figure 1.

In section 4 the results of Theorem 1 will be applied to the standard Hill-type form of the killing curve, leading to explicit expressions for c_{opt} , T_{opt} .

We have formulated our problem and solution in terms of minimizing the AUC subject to achieving a given log-reduction LR_{target} , but an equivalent problem is to maximize the log-reduction LR_{max} subject to a given AUC - since AUC is proportional to the cumulative dosage this problem will arise if we want to maximize the efficacy of a given total dose of the antimicrobial. We can re-formulate the result of Theorem 1 as follows:

Corollary 1. Given a value AUC, the concentration profile C(t) satisfying AUC[C(t)] = AUC and inducing the maximal log-reduction $LR_{max}[C(t)]$ is given by (3.1), where c_{opt} is the unique solution of (3.3), and

$$T_{opt} = \frac{AUC}{c_{opt}}.$$

The value of LR_{max} attained by this optimal profile is

$$LR_{opt} = \frac{1}{\ln(10)} \cdot \frac{k(c_{opt}) - r}{c_{opt}} \cdot AUC.$$
(3.6)

We now begin the analysis leading to the proof of Theorem 1. As a first step, we consider only the specific class of concentration profiles which take a constant value c for a duration T_f (the final time), that is:

$$C(t) = \begin{cases} c & 0 \le t \le T_f \\ 0 & t > T_f \end{cases}$$
 (3.7)

Among these profiles, we will now find the one which achieves the log-reduction LR_{target} with minimal AUC. We emphasize that the restriction to profiles of the form (3.7) is only temporary - we will later prove that the resulting concentration profile is in fact optimal among all concentration profiles satisfying $LR_{max}[C(t)] = LR_{target}$.

The log-reduction up to an arbitrary time $T \ge 0$, corresponding to the concentration profile (3.7), is (see (2.10))

$$LR(T) = \frac{1}{\ln(10)} \cdot \int_0^T [k(C(t)) - r] dt = \frac{1}{\ln(10)} \cdot \begin{cases} T \cdot (k(c) - r) & T \le T_f \\ T_f \cdot k(c) - T \cdot r & T > T_f \end{cases},$$

which is increasing for $T \leq T_f$ and decreasing for $T \geq T_f$, hence

$$LR_{max} = \max_{T \ge 0} LR(T) = LR(T_f) = \frac{1}{\ln(10)} \cdot T_f \cdot (k(c) - r).$$

Therefore to achieve a target log-reduction LR_{target} using the constant concentration c we need to choose

$$T_f = \frac{\ln(10) \cdot LR_{target}}{k(c) - r}.$$
(3.8)

The AUC corresponding to this profile is

$$AUC = T_f \cdot c = \ln(10) \cdot LR_{target} \cdot \frac{c}{k(c) - r}$$

Thus to minimize the AUC we need to maximize the function $f_r: (0, \infty) \to \mathbb{R}$ defined by (3.2) over all c > 0. The existence of this maximizer, and the fact that it is the unique critical point of f_r , is shown in the following Lemma:

Lemma 1. Assume k(c) satisfies (A1)-(A3), and $\alpha > 1$. Then the function f_r defined by (3.2) has a unique critical point c_{opt} , that is a value satisfying

$$f'_r(c) = 0 \quad \Leftrightarrow \quad k'(c) = \frac{k(c) - r}{c}, \tag{3.9}$$

which is a global maximizer of f_r .

In the sigmoidal case (see (A3)(ii)), we always have $c_{opt} > c_{infl}$, where c_{infl} is the inflection point of k(c).

Proof of Lemma 1. Using (A1),(A2) and the assumption $\alpha > 1$, we have

$$c < zMIC \implies f_r(c) < 0, \quad c > zMIC \implies f_r(c) > 0,$$
$$\lim_{c \to +\infty} f_r(c) = 0.$$

These facts imply that $f_r(c)$ has a global maximizer on $(0, \infty)$, which we denote by c_{opt} .

It remains to show that c_{opt} is the unique critical point of $f_r(c)$. We have

$$f'_r(c) = \frac{k'(c) - \frac{k(c)}{c}}{c} + \frac{r}{c^2} = \frac{r - h(c)}{c^2}$$
(3.10)

where

$$h(c) = k(c) - ck'(c), \qquad (3.11)$$

so any critical point of $f_r(c)$ satisfies h(c) = r. Note that

$$h'(c) = -ck''(c), (3.12)$$

hence:

(a) if k is concave then h'(c) > 0, so h(c) is increasing in $(0, \infty)$, hence the critical point c_{opt} of $f_r(c)$ is unique.

(b) If k is sigmoidal, then h'(c) > 0 for $c > c_{infl}$, hence h(c) is increasing in this range, so that $f_r(c)$ has at most one critical point in the interval $[c_{infl}, \infty)$. To prove uniqueness it therefore suffices to show that $f_r(c)$ has no critical point in $[0, c_{infl}]$. But note that since k(c) is convex on $[0, c_{infl}]$, hence k'(c) is increasing on this interval, we have

$$c \in (0, c_{infl}] \Rightarrow k'(c) = \frac{1}{c} \int_0^c k'(c) du > \frac{1}{c} \int_0^c k'(u) du = \frac{k(c)}{c},$$
 (3.13)

hence, by (3.10), $f'_r(c) > 0$ for $c \in (0, c_{infl}]$. Note that this also shows that $c_{opt} > c_{infl}$.

The above considerations show that the optimal concentration profile, among those of the form (3.7) which achieve LR_{target} , is given by (3.1), with c_{opt} given by (3.3), and T_{opt} given by (3.4).

We now show that the profile $C_{opt}(t)$ is in fact optimal among all concentration profiles which achieve LR_{target} , and is thus the solution to Problem 1:

Proof of Theorem 1. We have, for any c > 0,

$$k(c) - r = c \cdot \frac{k(c) - r}{c} \le c \cdot \max_{c' > 0} \frac{k(c') - r}{c'},$$

and in view of Lemma 1 this implies

$$k(c) - r \le c \cdot \frac{k(c_{opt}) - r}{c_{opt}},$$
(3.14)

which is also valid for c = 0.

Let C(t) be any concentration profile with $LR_{max}[C(t)] = LR_{target}$, and let $T^* > 0$ be a value for which $LR(T^*) = LR_{max}[C(t)]$. We then have, using (3.14)

$$\ln(10) \cdot LR_{target} = \ln(10) \cdot LR(T^*) = \int_0^{T^*} [k(C(t)) - r] dt \qquad (3.15)$$
$$\leq \frac{k(c_{opt}) - r}{c_{opt}} \cdot \int_0^{T^*} C(t) dt$$
$$\leq \frac{k(c_{opt}) - r}{c_{opt}} \cdot \int_0^\infty C(t) dt = \frac{k(c_{opt}) - r}{c_{opt}} \cdot AUC$$

so that

$$AUC \ge \ln(10) \cdot LR_{target} \cdot \frac{c_{opt}}{k(c_{opt}) - r} = AUC_{opt}, \qquad (3.16)$$

where AUC_{opt} is given by (3.5), so we see that AUC cannot be made smaller AUC_{opt} . Therefore $C_{opt}(t)$ is a minimizer.

To show uniqueness of the minimizer, note that if we have equality in (3.16), hence in (3.15), then it must be the case that, for almost every $t \in [0, T^*]$,

$$k(C(t)) - r = \frac{k(c_{opt}) - r}{c_{opt}} \cdot C(t) \quad \Rightarrow \quad \frac{k(C(t)) - r}{C(t)} = \max_{c > 0} \frac{k(c) - r}{c},$$

implying that $C(t) = c_{opt}$, for almost every $t \in [0, T^*]$, as well as that

$$\int_0^{T^*} C(t)dt = \int_0^\infty C(t)dt,$$

implying that C(t) = 0 for *a.e.* $t \ge T^*$. We therefore have

$$LR_{max}[C(t)] = \frac{1}{\ln(10)} \cdot T^* \cdot (k(c_{opt}) - r),$$

implying that

$$T^* = \frac{\ln(10) \cdot LR_{target}}{k(c_{opt}) - r} = T_{opt}.$$

We have thus shown that $C(t) = C_{opt}(t)$ for *a.e.* t, establishing uniqueness.

The assumption (A3) that k(c) is either concave or sigmoidal, plays only a limited role in the proof of Theorem 1 - it was used to prove that the maximizer c_{opt} of $f_r(c)$ is unique, and that c_{opt} is the unique solution of (3.3) (Lemma 1). The existence of a global maximizer of $f_r(c)$ follows from (A1),(A2) (see proof of Lemma 1), and any such global maximizer c_{opt} gives rise to a solution $C_{opt}(t)$ of Problem 1, defined by (3.1). If (A3) does not hold (note that (A1),(A2) imply that k(c) cannot be convex, but it can have more than one inflection point), then it is possible that $f_r(c)$ will have critical points which are not global maximizers, which will thus not give rise to solutions of Problem 1, or that the global maximum will be attained at more than one point, in which case there will be two or more solutions of Problem 1, all giving rise to the same AUC. However, kill-rate functions employed in practice are either concave or sigmoidal, hence (A3) is satisfied.

We conclude this section by considering a variant of Problem 1, which will be relevant under some circumstances. A notable feature of the the optimization problem that we have posed and solved above is the fact that neither the duration of treatment, nor the time T^* at which eradication is achieved, are constrained in advance - rather they are determined as part of the solution of the problem (and turn out to be equal). This allows for maximal flexibility in achieving the aim of minimizing the AUC. A potential disadvantage arises in case that the duration T_{opt} until eradication is judged to be too long, in which case we might be willing to accept a higher value of AUCin order achieve a lower value of the time T^* to eradication. We can thus formulate a *time-restricted* version of Problem 1, in which we pre-determine a maximal allowed duration \hat{T} to eradication:

Problem 2 (Time-restricted version of Problem 1). Given a target value LR_{target} and a maximal duration \hat{T} , find a concentration profile C(t) such that there exists a time $T \leq \hat{T}$ for which $LR(T) = LR_{target}$ (where LR(T) is given by (2.10)), with the corresponding AUC (given by (2.1)) as small as possible.

The solution of this modified problem, given in the following theorem, is different for \hat{T} in different ranges.

Theorem 2. Assume (A1)-(A3) and $\alpha > 1$. Let a value LR_{target} and a maximal duration \hat{T} be given. Then

- (i) If $\hat{T} \ge T_{opt}$, the solution of Problem 2 coincides with the solution $C_{opt}(t)$ of problem 1.
- (ii) If

$$\hat{T} \le T_{min} \doteq \frac{\ln(10) \cdot LR_{target}}{k_{max} - r} \tag{3.17}$$

then it is **impossible** to achieve eradication within such a short time, so that the problem has no solution.

(iii) In the intermediate range, $T_{min} < \hat{T} < T_{opt}$, the solution of Problem 2 consists of a constant concentration \hat{c} , applied for the entire time duration up to time \hat{T} :

$$\hat{C}(t) = \begin{cases} \hat{c} & 0 \le t \le \hat{T} \\ 0 & t > \hat{T}, \end{cases}$$
(3.18)

where \hat{c} is determined by the equation

$$\hat{T} \cdot [k(\hat{c}) - r] = \ln(10) \cdot LR_{target}.$$
(3.19)

Thus, while the lowest AUC will be achieved by the profile $C_{opt}(t)$ given by (3.1) in time T_{opt} , if one wishes to achieve eradication in a shorter time $\hat{T} < T_{opt}$, one can do so, at the price of a higher AUC, as long as $\hat{T} > T_{min}$. In this case the lowest AUCthat can be achieved - which will be higher than AUC_{opt} - will be attained by chosing the profile $\hat{C}(t)$ according to (3.18),(3.19).

We note that the numerical examples in the following section show that, for realistic parameter values, the optimal duration T_{opt} is quite reasonable - on the order of a few days when the doubling time of the microbial population in the absence of antimicrobial is on the order of hours. Hence in most practical cases there might not be need to restrict the time duration to be below T_{opt} , though this might change when considering critical cases in which fast reduction of the microbial load is required.

Proof of Theorem 2. (i) is trivially true, since if $\hat{T} > T_{opt}$ then $C_{opt}(t)$ leads to eradication before time \hat{T} , and, by Theorem 1 it achieves the lowest possible value of AUC.

(ii) If $\hat{T} \leq T_{min}$ then for any $T \leq \hat{T}$ we have

$$\ln(10) \cdot LR(T) = \int_0^T [k(C(t)) - r] dt < T \cdot [k_{max} - r] \le T_{min} \cdot [k_{max} - r] = \ln(10) \cdot LR_{target},$$

so that the target reduction cannot be achieved.

(iii) Assume now that

$$T_{min} < \hat{T} < T_{opt}. \tag{3.20}$$

Note first that $\hat{T} > T_{min}$ implies that, using (A2)

$$\lim_{c \to \infty} \hat{T} \cdot [k(c) - r] = \hat{T} \cdot [k_{max} - r] > T_{min} \cdot [k_{max} - r] = \ln(10) \cdot LR_{target},$$

hence by (A1) the equation (3.19) has a unique solution \hat{c} .

(3.19) implies that

$$\frac{1}{\ln(10)} \int_0^{\hat{T}} [k(\hat{C}(t)) - r] dt = \hat{T} \cdot [k(\hat{c}) - r] = LR_{target},$$

so that the profile $\hat{C}(t)$ achieves eradication at time \hat{T} .

To show that $\hat{C}(t)$, defined by (3.18) is the solution of Problem 2, we assume that C(t) is any concentration profile for which $LR(T) = LR_{target}$, where $T \leq \hat{T}$, and we need to show that if $AUC[C(t)] \geq AUC[\hat{C}(t)]$, with equality iff $C(t) = \hat{C}(t)$ for *a.e.* t. By (3.19),(3.20), and (3.4), we have

 $k(\hat{c}) - r = \frac{\ln(10) \cdot LR_{target}}{\hat{T}} > \frac{\ln(10) \cdot LR_{target}}{T_{opt}} = k(c_{opt}) - r,$

 $\hat{c} > c_{opt}.$

which, by (A1), implies

We now define

$$\hat{r} = k(\hat{c}) - \hat{c}k'(\hat{c}),$$
(3.22)

and claim that

$$\hat{r} > r. \tag{3.23}$$

(3.21)

To show this we recall that in the proof of Lemma 1 it was shown that the function h(c) defined by (3.11) is monotone increasing for all c > 0 in the concave case, and for all $c > c_{infl}$ in the sigmoidal case, in which case we also have $c_{opt} > c_{infl}$. Therefore, since $h(c_{opt}) = r$ and $h(\hat{c}) = \hat{r}$, (3.21) implies (3.23).

By (3.22) we have

$$k'(\hat{c}) = \frac{k(\hat{c}) - \hat{r}}{\hat{c}},$$

which, using Lemma 1, applied with \hat{r} replacing r, implies that \hat{c} is the maximizer of $f_{\hat{r}}(c)$, so that

$$\frac{k(\hat{c})-\hat{r}}{\hat{c}} = \max_{c>0} \frac{k(c)-\hat{r}}{c}$$

We therefore have, for all c > 0,

$$k(c) - \hat{r} \le c \cdot \frac{k(\hat{c}) - \hat{r}}{\hat{c}}.$$
(3.24)

If C(t) is a concentration profile for which $LR(T) = LR_{target}$, where $T \leq \hat{T}$, then we have, using (3.23), (3.24)

$$\ln(10) \cdot LR_{target} = \int_{0}^{T} [k(C(t)) - r] dt = \int_{0}^{T} [k(C(t)) - \hat{r}] dt + T \cdot (\hat{r} - r)$$

$$\leq \int_{0}^{T} [k(C(t)) - \hat{r}] dt + \hat{T} \cdot (\hat{r} - r) \leq \frac{k(\hat{c}) - \hat{r}}{\hat{c}} \int_{0}^{T} C(t) dt + \hat{T} \cdot (\hat{r} - r)$$

$$\leq \frac{k(\hat{c}) - \hat{r}}{\hat{c}} \cdot AUC[C(t)] + \hat{T} \cdot (\hat{r} - r), \qquad (3.25)$$

which, together with (3.19), implies

$$AUC[C(t)] \ge \left[\ln(10) \cdot LR_{target} - \hat{T} \cdot (\hat{r} - r)\right] \cdot \frac{\hat{c}}{k(\hat{c}) - \hat{r}}$$

$$= \left[\hat{T} \cdot [k(\hat{c}) - r] - \hat{T} \cdot (\hat{r} - r)\right] \cdot \frac{\hat{c}}{k(\hat{c}) - \hat{r}} = \hat{T} \cdot \hat{c} = AUC[\hat{C}(t)],$$

proving that $\hat{C}(t)$ indeed attains the minimal AUC among the relevant concentration profiles. To show uniqueness, note that the equality $AUC[C(t)] = AUC[\hat{C}(t)]$ can hold only if all inequalities in (3.25) are in fact equalities, which in particular implies $T = \hat{T}$ and $k(C(t)) = k(\hat{c})$, hence $C(t) = \hat{c}$ for *a.e.* $0 \le t \le \hat{T}$, and also that $\int_{\hat{T}}^{\infty} C(t)dt = 0$, so that C(t) = 0 for *a.e.* $t > \hat{T}$, hence $C(t) = \hat{C}(t)$ *a.e.*.

4 Application to Hill-type pharmacodynamic functions

We now specialize the results to the case that the kill-rate function is the Hill function $k_H(c)$ defined by (2.6), which allows us to obtain explicit expressions for the quantities of interest. We use these expressions to study the dependence of c_{opt} and T_{opt} on the relevant parameters.

In the case of a Hill-type pharmacodynamic function (3.2) gives

$$f_r(c) = \frac{1}{c} \left(k_{max} \cdot \frac{c^{\gamma}}{C_{50}^{\gamma} + c^{\gamma}} - r \right) = \frac{r}{c} \left(\alpha \cdot \frac{c^{\gamma}}{C_{50}^{\gamma} + c^{\gamma}} - 1 \right),$$

where α is the antimicrobial potency given by (2.7). Solving the equation $f'_r(c) = 0$, which is equivalent to

$$(\alpha - 1) \left(\frac{c}{C_{50}}\right)^{2\gamma} - ((\gamma - 1)\alpha + 2)) \left(\frac{c}{C_{50}}\right)^{\gamma} - 1 = 0,$$

we find that the optimal concentration is

$$c_{opt} = c_{opt}(\gamma, \alpha) = C_{50} \cdot (\alpha - 1)^{-\frac{1}{\gamma}} \cdot \left[1 + \alpha \cdot \left(\frac{\gamma - 1}{2} + \sqrt{\left(\frac{\gamma - 1}{2} \right)^2 + \frac{\gamma}{\alpha}} \right) \right]^{\frac{1}{\gamma}}, \quad (4.1)$$

and substituting this into (3.4) we find that the time T_{opt} for which this concentration should be maintained is

$$T_{opt} = T_{opt}(\gamma, \alpha) = T_2 \cdot \frac{\ln(10) \cdot LR_{target}}{\ln(2)(\alpha - 1)} \cdot \left[1 + \frac{\alpha}{\gamma} \cdot \left(\sqrt{\left(\frac{\gamma - 1}{2}\right)^2 + \frac{\gamma}{\alpha}} - \frac{\gamma - 1}{2} \right) \right],$$
(4.2)

where T_2 is the microbial doubling time in the absence of antimicrobial (see (2.2)). Note that:

• The optimal concentration c_{opt} is linearly dependent on the half-saturation concentration C_{50} . Therefore in our presentation of numerical results below we provide the values of the dimensionless ratio $\frac{C_{opt}}{C_{50}}$.

- The optimal duration T_{opt} is linearly dependent on the target log-reduction LR_{target} , as well as on the microbial doubling time T_2 . Therefore in presentation of numerical results we provide the values of the dimensionless ratio $\frac{T_{opt}}{T_2}$. Note that T_{opt} does not depend on the value of the half-saturation constant C_{50} .
- As a consequence of the above and of (3.5), the value AUC_{opt} depends linearly on both T_2 and C_{50} , so that in the presentation of numerical results we provide the value of the dimensionless ratio $\frac{AUC}{T_2 \cdot C_{50}}$.
- In the special case $\gamma = 1$, which is commonly employed (referred to as the E_{max} model Meibohm and Derendorf (1997)), the somewhat complicated expressions given above simplify to

$$\gamma = 1 \Rightarrow c_{opt} = \frac{C_{50}}{\sqrt{\alpha} - 1}, \quad T_{opt} = T_2 \cdot \frac{\ln(10) \cdot LR_{target}}{\ln(2)(\sqrt{\alpha} - 1)}.$$

Table 2 presents the optimal concentration, duration, and AUC for parameter values in the range which is typical for most antimicrobials. According to studies estimating parameters for various antimicrobials, reviewed in (Czock and Keller (2007)), the Hill coefficient of γ is in most cases in the range 0.5-5, and the potency $\alpha = \frac{k_{max}}{r}$ is mostly in the range 2-6. In the calculation of T_{opt} and AUC_{opt} we have taken $LR_{target} = 7$ – in view of the linear dependence of these quantities on LR_{target} , to obtain T_{opt} , AUC_{opt} for any value of LR_{target} one simply needs to multiply the value in the table by $\frac{LR_{target}}{7}$. Note that the quantities $\frac{c_{opt}}{C_{50}}, \frac{T_{opt}}{T_2}, \frac{AUC_{opt}}{T_2, C_{50}}$ presented in these tables, as well as the parameters α, γ which they depend on, are all non-dimensional, so that the numbers are valid independently of the units used to measure concentration and time.

We can use the explicit expressions (4.1), (4.2) to study the nature of the dependence of c_{opt} and T_{opt} on the drug potency α and the Hill exponent γ . The results are given in Propositions 1,2 - we omit the derivation of these results since they are routine applications of elementary calculus arguments.

The following proposition shows that higher antimicrobial potency α leads the optimal concentration profile to involve both a lower concentration and a shorter duration (see also Figure 2).

Proposition 1. (a) For fixed $\gamma > 0$, the function $c_{opt}(\alpha) = c_{opt}(\gamma, \alpha)$ ($\alpha > 1$) is monotone decreasing, with

$$\lim_{\alpha \to 1+} c_{opt}(\alpha) = +\infty.$$
(4.3)

and

- (i) In the concave case $\gamma \leq 1$: $\lim_{\alpha \to \infty} c_{opt}(\alpha) = 0$.
- (ii) In the sigmoidal case $\gamma > 1$: $\lim_{\alpha \to \infty} c_{opt}(\alpha) = C_{50} \cdot (\gamma 1)^{\frac{1}{\gamma}} > 0$.

(b) For fixed $\gamma > 0$, the function $T_{opt}(\alpha) = T_{opt}(\gamma, \alpha)$ ($\alpha > 1$) is monotone decreasing, with

$$\lim_{\alpha \to 1+} T_{opt}(\alpha) = +\infty, \quad \lim_{\alpha \to \infty} T_{opt}(\alpha) = 0.$$
(4.4)

Optimal concentration $\frac{c_{opt}}{C_{EQ}}$

-		C_{50}					
$\gamma \alpha$	2.0	3.0	4.0	5.0	6.0		
0.5	2.62	0.71	0.33	0.19	0.13		
1.0	2.41	1.37	1.00	0.81	0.69		
2.0	2.06	1.64	1.47	1.37	1.31		
3.0	1.83	1.60	1.51	1.46	1.42		
4.0	1.69	1.54	1.48	1.44	1.42		
5.0	1.59	1.48	1.43	1.41	1.39		

Optimal duration $\frac{T_{opt}}{T}$

		+ 2			
$\gamma \alpha$	2.0	3.0	4.0	5.0	6.0
0.5	98.5	62.5	50.1	43.8	39.9
1.0	56.1	31.8	23.3	18.8	16.0
2.0	37.6	19.6	13.4	10.3	8.3
3.0	32.3	16.4	11.1	8.4	6.7
4.0	29.8	15.1	10.1	7.6	6.1
5.0	28.4	14.3	9.6	7.2	5.8

Optimal AUC $\frac{AUC_{opt}}{T_{0}Cro}$

$\gamma \alpha$	2.0	3.0	4.0	5.0	6.0
0.5	257.9	44.4	16.7	8.5	5.1
1.0	135.5	43.4	23.3	15.2	11.1
2.0	77.4	32.1	19.7	14.1	10.9
3.0	59.1	26.4	16.7	12.2	9.6
4.0	50.3	23.1	14.9	11.0	8.7
5.0	45.0	21.1	13.7	10.1	8.0

Table 2 Optimal concentration profiles for different values of $\alpha = \frac{k_{max}}{r}$ and of the Hill exponent γ . Top: Optimal concentration $\frac{c_{opt}}{C_{50}}$, Middle: optimal duration $\frac{T_{opt}}{T_2}$ for achieving log-reduction $LR_{target} = 7$. Bottom: value of $\frac{AUC}{T_2 \cdot C_{50}}$ attained by the optimal schedule, assuming $LR_{target} = 7$.

The dependence of c_{opt} , T_{opt} on the Hill exponent γ is described in the next proposition. Note that the shape of the function $c_{opt}(\gamma)$ is different for $\alpha < 2$, $\alpha = 2$, and $\alpha > 2$ - see also Figure 3.

Proposition 2. (a) For fixed $\alpha > 1$, the function $c_{opt}(\gamma) = c_{opt}(\gamma, \alpha)$ satisfies

$$\lim_{\gamma \to \infty} c_{opt}(\gamma) = C_{50},\tag{4.5}$$

and

- (i) If $1 < \alpha < 2$ then $c_{opt}(\gamma)$ is monotone decreasing, with $\lim_{\gamma \to 0+} c_{opt}(\gamma) = +\infty$.
- (ii) If $\alpha = 2$ then $c_{opt}(\gamma)$ is monotone decreasing, with $\lim_{\gamma \to 0+} c_{opt}(\gamma) = e \cdot C_{50}$.
- (iii) If $\alpha > 2$, then $c_{opt}(\gamma)$ is increasing for small γ and decreasing for large γ , and $\lim_{\gamma \to 0+} c_{opt}(\gamma) = 0$.



Fig. 2 The parameters defining the 'ideal' concentration profile as functions of the drug potency $\alpha = \frac{k_{max}}{r}$, for different values of the Hill exponent γ . Left: the ratio of c_{opt} to the half-saturation value C_{50} of the antimicrobial. Right: the ratio of T_{opt} to the microbial doubling time T_2 . Here it is assumed that $LR_{target} = 7$.



Fig. 3 The parameters defining the optimal concentration profile as functions of the Hill exponent γ , for different values of the potency α . Left: the ratio of c_{opt} to the half-saturation value C_{50} of the antimicrobial. Right: the ratio of T_{opt} to the microbial doubling time T_2 . Here it is assumed that $LR_{target} = 7$.

(b) For any $\alpha > 1$, the function $T_{opt}(\gamma) = T_{opt}(\gamma, \alpha)$ is monotone decreasing, with

$$\lim_{\gamma \to 0+} T_{opt}(\gamma) = +\infty, \quad \lim_{\gamma \to \infty} T_{opt}(\gamma) = 0$$

5 Pharmacokinetic considerations: the optimal bolus+continuous dosing schedule

In the preceding analysis we considered arbitrary antimicrobial concentration profiles C(t). In practice, however, the concentration profile cannot be chosen at will, since it is the result of a dosage plan and of the pharmacokinetics of the drug. Thus, while the concentration profile given by Theorem 1 is the optimal one, we show below that it is impossible to achieve this profile precisely, due the fact that the optimal profile $C_{opt}(t)$ has a discontinuity at $t = T_{opt}$, while realistic pharmacokinetics precludes such a sharp cutoff. It then becomes of interest to approximate the 'ideal' concentration profile, to the extent possible, by a *pharmacokinetically feasible* one. We will consider one simple and natural method of doing so, and determine its optimal version.

We assume a basic one-compartment pharmacokinetic model with first order degradation kinetics - a reasonable choice for most commonly prescribed antimicrobials (Bouvier d'Yvoire and Maire (1996)). The dosing rate - the rate at which antimicrobial is added into the compartment, will be denoted by d(t). The concentration profile is then given by the solution of the differential equation

$$\frac{dC}{dt} = V^{-1}d(t) - \mu C(t), \quad C(0) = 0,$$
(5.1)

where V is the volume of distribution and μ is the degradation/removal rate of the antimicrobial, so that

$$\tau = \frac{\ln(2)}{\mu} \tag{5.2}$$

is the antimicrobial half-life. Making the natural assumption that the cumulative dose

$$D = \int_0^\infty d(t) dt$$

is finite, it follows that $C(\infty) = \lim_{t\to\infty} C(t) = 0$, so that, by integrating (5.1) over $[0,\infty)$ we obtain

$$0 = C(\infty) - C(0) = V^{-1} \int_0^\infty d(t) dt - \mu \cdot AUC$$

hence

$$AUC = \mu^{-1} V^{-1} D, (5.3)$$

a relation that is well-known in pharmacokinetics (Derendorf and Schmidt (2019), Rescigno (2003)). Note that this shows that the objective of minimizing the AUCis equivalent to that of minimizing the cumulative dose. An analogous linear relation between cumulative dosage D and AUC can be derived for more complicated (multicompartment) pharmacokinetics.

The solution of (5.1) is given by

$$C(t) = V^{-1} \int_0^t e^{-\mu(t-s)} d(s) ds.$$
(5.4)

We note that (5.4) is meaningful even if d(t) is not a function, but is rather an arbitrary non-negative measure - and may therefore include δ -functions which represent *bolus doses*, that is a finite amount of antimicrobial which is injected instantaneously, as we shall do below. In any case, C(t) given by (5.4) will be positive for all t > 0 sufficiently large, so that the function $C_{opt}(t)$ given by (3.1) cannot be represented in the form (5.4), that is, it is not pharmacokinetically feasible.

We can, however, generate concentration profiles which take a constant value \bar{c} for a duration $0 \leq t \leq T_{bc}$ by administering a bolus loading dose of size $V\bar{c}$, at time t = 0to raise the concentration to \bar{c} , and thereafter supplying the drug as a continuous infusion at rate $\mu V \bar{c}$ up to time T_{bc} , so as to maintain the concentration \bar{c} . This is known as a *bolus+continuous* (*bc*) dosage schedule (Derendorf and Schmidt (2019)). Note that in order to achieve reduction in the microbial load we must take $\bar{c} > zMIC$. The expression for this dosing schedule is thus

$$d_{bc}(t) = V\bar{c} \cdot [\delta(t) + \mu \cdot H(T_{bc} - t)], \qquad (5.5)$$

where the δ -function represents the bolus dose, and H is the Heaviside function: H(t) = 0 for t < 0 and H(t) = 1 for $t \ge 0$.

The resulting concentration profile, given by the solution of (5.1), will be

$$C_{bc}(t) = \begin{cases} \bar{c} & t \le T_{bc} \\ \bar{c}e^{-\mu(t-T_{bc})} & t > T_{bc} \end{cases}.$$
 (5.6)

We now formulate and study the problem of optimizing a bolus+continuous dosing schedule.

Problem 3. Given a target value LR_{target} , find, among all dosing schedules of the form (5.5), parameterized by \bar{c} and T_{bc} , for which the corresponding log-reduction is $LR_{max}[C_{bc}(t)] = LR_{target}$, the one for which the AUC is minimal.

The solution of this problem is given by

Theorem 3. Assume (A1)-(A3) and $\alpha > 1$. Define

$$\rho = \int_{zMIC}^{c_{opt}} \frac{k(u) - r}{u} du, \qquad (5.7)$$

where zMIC is the solution of (2.8) and c_{opt} is the solution of (3.3).

Then:

(i) If $\rho < \ln(10) \cdot LR_{target} \cdot \mu$, then the solution of Problem 3 is given by

$$d_{opt}(t) = V \cdot c_{opt} \cdot [\delta(t) + \mu \cdot H(T_{bc,opt} - t)], \qquad (5.8)$$

where

$$T_{bc,opt} = \frac{\ln(10) \cdot LR_{target} - \mu^{-1}\rho}{k(c_{opt}) - r}.$$
(5.9)

The resulting concentration profile, given by the solution of (5.1), is

$$C_{bc,opt}(t) = \begin{cases} c_{opt} & t \le T_{bc,opt} \\ c_{opt}e^{-\mu(t-T_{bc,opt})} & t > T_{bc,opt} \end{cases}.$$
 (5.10)

The target log-reduction LR_{target} of the microbial population will be achieved at time

$$T^* = T_{bc,opt} + \frac{1}{\mu} \cdot \ln\left(\frac{c_{opt}}{zMIC}\right),\tag{5.11}$$

and the corresponding AUC is

$$AUC_{bc,opt} = \left[\mu^{-1} + \frac{\ln(10) \cdot LR_{target} - \mu^{-1}\rho}{k(c_{opt}) - r}\right] \cdot c_{opt}.$$
 (5.12)

(ii) If $\rho \geq \ln(10) \cdot LR_{target} \cdot \mu$, the solution of Problem 3 is given by

$$d_{opt}(t) = Vc^*\delta(t),$$

where c^* is the solution of the equation

$$\int_{zMIC}^{c^*} \frac{k(u) - r}{u} du = \ln(10) \cdot LR_{target} \cdot \mu, \qquad (5.13)$$

so that

$$C_{bc,opt}(t) = c^* e^{-\mu t}.$$

The target microbial population will be reached at time

$$T^* = \frac{1}{\mu} \cdot \ln\left(\frac{c^*}{zMIC}\right),$$

and

$$AUC_{bc,opt} = \mu^{-1}c^*.$$

We thus see that:

(i) If $\rho < \ln(10) \cdot LR_{target} \cdot \mu$, corresponding to sufficiently high decay rate of the antimicrobial, the optimal bolus+continuous dosing schedule maintains the *same* constant concentration c_{opt} as the 'ideal' concentration profile $C_{opt}(t)$ of Theorem 1, but for shorter time duration. Indeed from (3.4) and (5.9) we have

$$T_{opt} - T_{bc,opt} = \frac{\tau}{\ln(2)} \cdot \frac{\rho}{k(c_{opt}) - r} > 0.$$
 (5.14)

We note also that, since c_{opt} maximizes the function $f_r(c)$ given by (3.2), we have the inequality

$$\rho = \int_{zMIC}^{c_{opt}} \frac{k(u) - r}{u} du \le (c_{opt} - zMIC) \cdot \frac{k(c_{opt}) - r}{c_{opt}},$$
(5.15)

so that (5.14) implies

$$0 < T_{opt} - T_{bc,opt} \le \frac{\tau}{\ln(2)} \cdot \left(1 - \frac{zMIC}{c_{opt}}\right)$$

This implies that, as the antimicrobial half-life τ becomes short, $T_{bc,opt}$ converges to T_{opt} , so that the concentration profile induced by the optimal bolus+continuous schedule approaches the 'ideal' optimal schedule $C_{opt}(t)$. The AUC achieved by the optimal bolus+continuous schedule will of course be higher than that obtained using the 'ideal' concentration profile attaining the same log-reduction LR_{target} . Indeed from (3.5),(5.12) and (5.15) we have

$$AUC_{bc,opt} - AUC_{opt} = \frac{\tau}{\ln(2)} \cdot \left(1 - \frac{\rho}{k(c_{opt}) - r}\right) c_{opt} \ge \frac{\tau}{\ln(2)} \cdot zMIC.$$
(5.16)

As τ becomes small, (5.16) shows that the $AUC_{bc,opt}$ approaches AUC_{opt} .

(ii) If $\rho \geq \ln(10) \cdot LR_{target} \cdot \mu$, corresponding to a slow decay rate of the antimicrobial, the optimal dosing schedule consists of a single bolus dose raising the antimicrobial concentration to the value c^* at time t = 0. From (5.13) it follows that, as $\mu \to 0$,

$$c^* = zMIC + \frac{\ln(10) \cdot LR_{target}}{k'(zMIC)} \cdot \mu + o(\mu),$$

so that for small μ (long antimicrobial half-life) the optimal bolus dose raises the concentration to slightly above the pharmacodynamic minimal inhibitory concentration zMIC.

To begin the analysis leading to Theorem 3, we calculate the values LR_{max} and AUC corresponding to a bolus+continuous dosing schedule.

Lemma 2. Consider a bolus+continuous schedule $d_{bc}(t)$ (see (5.5)), with $\bar{c} > zMIC$, and the induced antimicrobial concentration profile $C_{bc}(t)$ (see (5.6)). Then:

(i) The maximal log-reduction corresponding to this concentration profile is

$$LR_{max} = \frac{1}{\ln(10)} \left[T_{bc} \cdot (k(\bar{c}) - r) + \mu^{-1} \phi(\bar{c}) \right], \qquad (5.17)$$

where the function $\phi(c)$ is defined by:

$$\phi(c) = \int_{zMIC}^{c} \frac{k(u) - r}{u} du.$$
(5.18)

(ii) The AUC corresponding to this dosage schedule is

$$AUC = [\mu^{-1} + T_{bc}] \cdot \bar{c}.$$
 (5.19)

Proof. (i) By (2.10), the log-reduction of the microbial load corresponding to (5.6), at time T, is

$$LR(T) = \frac{1}{\ln(10)} \cdot \int_0^T [k(C_{bc}(t)) - r] dt,$$

hence

$$T < T_{bc} \Rightarrow LR'(T) = k(C_{bc}(T)) - r = k(\bar{c}) - r > 0,$$

and

$$\lim_{T \to \infty} LR'(T) = \lim_{T \to \infty} (k(C_{bc}(T)) - r) = \lim_{T \to \infty} (k(\bar{c}e^{-\mu(T - T_{bc})}) - r) = -r < 0.$$

We thus have that LR(T) is an increasing function for $T < T_{bc}$, and a decreasing function for sufficiently large T, so that its maximum attained at some $T^* > T_{bc}$ satisfying $LR'(T^*) = 0$, that is

$$\begin{split} k(C_{bc}(T^*)) - r &= 0 \quad \Leftrightarrow \quad C_{bc}(T^*) = zMIC \quad \Leftrightarrow \quad \bar{c}e^{-\mu(T^* - T_{bc})} = zMIC \\ \Leftrightarrow \quad T^* = T_{bc} + \frac{1}{\mu} \cdot \ln\left(\frac{\bar{c}}{zMIC}\right). \end{split}$$

Using the change of variable $u = \bar{c}e^{-\mu(t-T_{bc})}$ in the integral below, we conclude that

$$\ln(10) \cdot LR_{max} = \ln(10) \cdot \max_{T>0} LR(T) = \ln(10) \cdot LR(T^*)$$

= $T_{bc} \cdot (k(\bar{c}) - r) + \int_{T_{bc}}^{T^*} \left[k \left(\bar{c}e^{-\mu(t-T_{bc})} \right) - r \right] dt$
= $T_{bc} \cdot (k(\bar{c}) - r) + \frac{1}{\mu} \int_{\bar{c}e^{-\mu(T^* - T_{bc})}}^{\bar{c}} \frac{k(u) - r}{u} du$
= $T_{bc} \cdot (k(\bar{c}) - r) + \frac{1}{\mu} \int_{zMIC}^{\bar{c}} \frac{k(u) - r}{u} du$
= $T_{bc} \cdot (k(\bar{c}) - r) + \mu^{-1} \phi(\bar{c}),$

where the function ϕ is defined by (5.18).

(ii) Using (5.3), the AUC corresponding to the concentration profile generated by the dosing schedule (5.5) is given by

$$AUC = V^{-1}\mu^{-1} \int_0^\infty d(t)dt = V^{-1}\mu^{-1} \left[V\bar{c} + \mu V\bar{c}T_{bc}\right] = \left[\mu^{-1} + T_{bc}\right] \cdot \bar{c}.$$

Proof of Theorem 3. By (5.17), in order to achieve a given log-reduction LR_{target} using a dosing schedule of the form (5.5), the parameters \bar{c}, T_{bc} defining this schedule must satisfy the constraint $LR_{max}[C(t)] = LR_{target}$, or

$$T_{bc} \cdot (k(\bar{c}) - r) + \mu^{-1} \phi(\bar{c}) = \ln(10) \cdot LR_{target}.$$
 (5.20)

We need to minimize the expression (5.19) over (\bar{c}, T_{bc}) , under the constraints (5.20) and

$$\bar{c} \ge zMIC, \quad T_{bc} \ge 0.$$
 (5.21)

The constraint (5.20) can be written as

$$T_{bc} = \frac{\ln(10) \cdot LR_{target} - \mu^{-1}\phi(\bar{c})}{k(\bar{c}) - r},$$
(5.22)

and the inequality constraints (5.21) imply that \bar{c} must satisfy

$$zMIC \le \bar{c} \le \phi^{-1}(\ln(10) \cdot LR_{target} \cdot \mu) = c^*, \qquad (5.23)$$

where c^* is the solution of (5.13).

Substituting (5.22) into (5.19) we get

$$AUC = AUC(\bar{c}) = \left[\mu^{-1} + \frac{\ln(10) \cdot LR_{target} - \mu^{-1}\phi(\bar{c})}{k(\bar{c}) - r}\right] \cdot \bar{c},$$
 (5.24)

which must be minimized over \bar{c} satisfying (5.23). Noting that the expression (5.24) goes to $+\infty$ when $\bar{c} \to zMIC$, we see that the minimum is attained either at (a) an interior point of the interval (5.23), or (b) at $\bar{c} = c^*$.

If $c_{opt} < c^*$, then since c_{opt} is the maximizer of $f_r(c)$ given by (3.2), we have

$$\begin{split} &\int_{c_{opt}}^{c^*} \frac{k(u) - r}{u} du < (c^* - c_{opt}) \cdot \frac{k(c_{opt}) - r}{c_{opt}} \\ \Leftrightarrow \quad \phi(c^*) - \phi(c_{opt}) < \frac{c^* - c_{opt}}{c_{opt}} \cdot (k(c_{opt}) - r) \\ \Leftrightarrow \quad \left[\mu^{-1} + \frac{\ln(10) \cdot LR_{target} - \mu^{-1}\phi(c_{opt})}{k(c_{opt}) - r} \right] \cdot c_{opt} < \mu^{-1}c^* \\ \Leftrightarrow AUC(c_{opt}) < AUC(c^*), \end{split}$$

so that the minimum of $AUC(\bar{c})$ in the interval (5.23) is attained at an interior point, at which $AUC'(\bar{c})$ must vanish, and using the fact that $\phi'(c) = \frac{k(c)-r}{c}$ we compute

$$AUC'(\bar{c}) = \frac{[\ln(10) \cdot LR_{target} - \mu^{-1}\phi(\bar{c})][k(\bar{c}) - r - k'(\bar{c}) \cdot \bar{c}]}{(k(\bar{c}) - r)^2}$$

$$\Leftrightarrow \quad k(\bar{c}) - r - k'(\bar{c}) \cdot \bar{c} = 0 \quad \Leftrightarrow \quad \bar{c} = c_{opt}.$$

Thus, from (5.22) we get (5.9), and from (5.19) we get (5.12).

On the other hand, if $c_{opt} \ge c^*$, the above calculation shows that the derivative of $AUC(\bar{c})$ does not vanish in the interior of the interval (5.23), so that the minimum is attained at $\bar{c} = c^*$, proving part (ii) of the theorem.

6 Optimal bolus+continuous dosing in the case of a Hill-type pharmacodynamic function

We now apply the results of Theorem 3 to the case in which k(c) is a Hill-type function (2.6), and provide numerical examples of the results obtained.

An explicit evaluation of the integral in (5.18) gives

$$\phi(c) = \frac{r}{\gamma} \cdot \ln\left(\frac{\left(1 + \left(\frac{c}{C_{50}}\right)^{\gamma}\right)^{\alpha}}{\left(\frac{c}{C_{50}}\right)^{\gamma}} \cdot \frac{(\alpha - 1)^{\alpha - 1}}{\alpha^{\alpha}}\right),$$

hence, using (4.1),

$$\rho = \phi(c_{opt}) = \frac{r}{\gamma} \cdot \ln\left(\frac{\left(\frac{\gamma+1}{2} + \sqrt{\left(\frac{\gamma-1}{2}\right)^2 + \frac{\gamma}{\alpha}}\right)^{\alpha}}{1 + \alpha \cdot \left(\frac{\gamma-1}{2} + \sqrt{\left(\frac{\gamma-1}{2}\right)^2 + \frac{\gamma}{\alpha}}\right)}\right),$$

and c^\ast is the solution of

$$\frac{\left(1 + \left(\frac{c^*}{C_{50}}\right)^{\gamma}\right)^{\alpha}}{\left(\frac{c^*}{C_{50}}\right)^{\gamma}} = 10^{LR_{target} \cdot \frac{\mu\gamma}{r}} \cdot \frac{\alpha^{\alpha}}{(\alpha - 1)^{\alpha - 1}}.$$
(6.1)

The condition $\rho < \ln(10) \cdot LR_{target} \cdot \mu$ holds iff

$$\tau < T_2 \cdot \gamma \cdot \ln(10) \cdot LR_{target} \cdot \left[\ln \left(\frac{\left(\frac{\gamma+1}{2} + \sqrt{\left(\frac{\gamma-1}{2}\right)^2 + \frac{\gamma}{\alpha}}\right)^{\alpha}}{1 + \alpha \cdot \left(\frac{\gamma-1}{2} + \sqrt{\left(\frac{\gamma-1}{2}\right)^2 + \frac{\gamma}{\alpha}}\right)} \right) \right]^{-1}.$$
 (6.2)

We thus have:

• If (6.2) holds, that is the antimicrobial half-life is sufficiently short, then the solution of Problem 3 is the bolus+continuous schedule (5.8), where c_{opt} is given by (4.1) and $T_{bc,opt}$ is given by

$$\frac{T_{bc,opt}}{T_2} = \frac{1}{\ln(2)(\alpha - 1)} \cdot \left(1 + \frac{1}{\frac{\gamma - 1}{2} + \sqrt{\left(\frac{\gamma - 1}{2}\right)^2 + \frac{\gamma}{\alpha}}}\right)$$
$$\times \left[\ln(10) \cdot LR_{target} - \frac{1}{\gamma} \cdot \ln\left(\frac{\left(\frac{\gamma + 1}{2} + \sqrt{\left(\frac{\gamma - 1}{2}\right)^2 + \frac{\gamma}{\alpha}}\right)^{\alpha}}{1 + \alpha \cdot \left(\frac{\gamma - 1}{2} + \sqrt{\left(\frac{\gamma - 1}{2}\right)^2 + \frac{\gamma}{\alpha}}\right)}\right) \cdot \frac{\tau}{T_2}\right].$$

Note that the value $T_{bc,opt}$ does not depend on the half-saturation constant C_{50} .

- If the reverse inequality to (6.2) holds, that is if the antimicrobial half-life is sufficiently long, then the solution of Problem 3 is a single bolus dose Vc^* , where c^* is given by (6.1).
- In the special case $\gamma = 1$ (the E_{max} model), the expression for $T_{bc,opt}$ reduces to

$$\gamma = 1 \quad \Rightarrow \quad \frac{T_{bc,opt}}{T_2} = \frac{1}{\ln(2)(\sqrt{\alpha} - 1)} \times \left[\ln(10) \cdot LR_{target} - \ln\left(\frac{(\sqrt{\alpha} + 1)^{\alpha - 1}}{\sqrt{\alpha^{\alpha}}}\right) \cdot \frac{\tau}{T_2} \right]$$

and the condition (6.2) reduces to positivity of the value on the right-hand side.

Tables 3,4 present numerical results regarding optimal bolus+continuous schedules, using the above formulae for parameter values which are in a range relevant to applications, which can be compared with the results concerning the 'ideal' concentration profile in Table 2. In Table 3 it is assumed that the ratio of the antimicrobial half-life to the microbial doubling time is $\frac{\tau}{T_2} = 4$, while in Table 4 we take faster antimicrobial decay, $\frac{\tau}{T_2} = 2$. For all parameter values considered, the condition (6.2) holds, so that the optimal schedule includes both a bolus and a continuous infusion. Comparing the AUC obtained in Table 3 with the 'ideal' ones in Table 2, we observe that, although, as expected, the values $AUC_{bc,opt}$ attained by the optimal bolus+continuous schedules are higher than AUC_{opt} , in most cases they lie within 25% of that value, with the exception of extreme cases of high Hill coefficient γ and antimicrobial potency α (e.g. for $\gamma = 5, \alpha = 6, AUC_{bc,opt}$ is 67.5% higher than AUC_{opt}). For shorter antimicrobial half-lives, as in Table 4, $AUC_{bc,opt}$ is even closer to AUC_{opt} . In general, we can conclude that for realistic parameter values, the optimal bolus+continuous dosing schedule attains outcomes which are quite close to the 'ideal' one. As an example, in Figure 4 we compare the 'ideal' concentration curve and the concentration curve induced by the optimal bolus+continuous schedule, and the corresponding microbial population curves, using parameters fitting the antibacterial Tobramycin applied to Pseudomonas aeruginosa ATCC 27853, as in the example of Bouvier d'Yvoire and Maire (1996) (see figure caption for parameter values). The duration of infusion in the optimal bolus+continuous schedule is $T_{bc,opt} = 31.3$ hours, slightly shorter than the duration $T_{opt} = 33.0$ of the 'ideal' concentration profile. For the 'ideal' concentration profile, the bacterial population reaches the target (eradication) value $10^{-7}B_0$ at $t = T_{opt}$, while for the optimal bolus+continuous schedule the target value is reached at time $T^* = 34.8$ hours (as given by (5.11)), that is 3.5 hours after antimicrobial infusion is ended. The AUC corresponding to the optimal bolus+continuous schedule is $5.82 \frac{mg \cdot h}{L}$, only 4% higher than the 'ideal' $AUC_{opt} = 5.59 \frac{mg \cdot h}{L}$.

In practice, the administration of a continuous dosing schedule requires the use of intravenous infusion, infusion pumps, or sustained/controlled release formulations. An intermittent dosing schedule, involving a series of bolus doses, is often opted for (Derendorf and Schmidt (2019)). It is intuitively obvious, however, and can be formally proved, that sufficiently frequent intermittent infusions, with appropriate doses, can be used to approximate a bolus+continuous schedule to with arbitrary precision, so that our results concerning the optimal bolus+continuous schedule are also relevant to the design of intermittent schedules, and in particular can be used to assess the

Optimal duration $\frac{T_{opt}}{T_{opt}}$

		- 2			
$\gamma \alpha$	2.0	3.0	4.0	5.0	6.0
0.5	95.7	59.5	47.0	40.7	36.7
1.0	53.5	28.9	20.2	15.7	12.8
2.0	35.4	17.1	10.8	7.5	5.5
3.0	30.3	14.3	8.8	6.0	4.3
4.0	28.0	13.2	8.1	5.5	4.0
5.0	26.8	12.6	7.8	5.3	3.9

Optimal	AUC	AUCopt
- I · · ·		10 (10

	1	2 0 30			
γ α γ	2.0	3.0	4.0	5.0	6.0
0.5	265.7	46.4	17.6	9.0	5.5
1.0	143.1	47.4	26.0	17.3	12.8
2.0	84.7	37.6	24.3	18.2	14.7
3.0	66.1	32.2	22.0	17.2	14.3
4.0	57.1	29.1	20.5	16.3	13.8
5.0	51.7	27.1	19.4	15.6	13.4

Table 3 Optimal bolus+continuous dosage plans for achieving log-reduction $LR_{target} = 7$, when the half-life of the antimicrobial satisfies $\frac{\tau}{T_2} = 4$, for different values of $\alpha = \frac{k_{max}}{r}$ and of the Hill exponent γ . The concentration c_{opt} to be maintained is the same as is Table 2. Top: Optimal duration of dosing, Bottom: value of AUC attained by the optimal schedule

Optimal duration $\frac{T_{opt}}{T_2}$

γ α γ	2.0	3.0	4.0	5.0	6.0
0.5	97.1	61.0	48.6	42.2	38.3
1.0	54.8	30.3	24.6	17.2	14.4
2.0	36.5	18.4	12.1	8.9	6.9
3.0	31.3	15.4	10.0	7.2	5.5
4.0	28.9	14.1	9.1	6.6	5.0
5.0	27.6	24.1	8.7	6.3	4.8

$\textbf{Optimal AUC} \; \tfrac{AUC_{opt}}{T_2 \cdot C_{50}}$						
$\gamma $ α γ	2.0	3.0	4.0	5.0	6.0	
0.5	261.8	45.4	17.2	8.8	5.3	
1.0	139.3	45.4	24.6	16.3	11.9	
2.0	81.1	34.8	22.0	16.2	12.8	
3.0	62.6	29.3	19.4	14.7	12.0	
4.0	53.7	26.1	17.7	13.6	11.2	
5.0	48.4	24.1	16.6	12.9	10.7	

Table 4 Optimal bolus+continuous dosage plans for achieving log-reduction $LR_{target} = 7$, when the half-life of the antimicrobial satisfies $\frac{\tau}{T_2} = 2$, for different values of $\alpha = \frac{k_{max}}{r}$ and of the Hill exponent γ . The concentration c_{opt} to be maintained is the same as is Table 2. Top: Optimal duration of dosing, Bottom: value of AUC attained by the optimal schedule



Fig. 4 Left: the 'ideal' optimal antimicrobial concentration profile (blue dashed line), and the concentration C(t) (in $\frac{mg}{L}$) at time t (in hours) induced by the optimal bolus+continuous schedule (red line), Right: The corresponding microbial populations relative to the initial population. Parameters, corresponding to the example from Bouvier d'Yvoire and Maire (1996) of Tobramycin applied to *Pseudomonas aeruginosa*, are: $C_{50} = 4.187 \frac{mg}{L}$, $k_{max} = 7.115h^{-1}$, $\gamma = 0.416$, $r = 0.995h^{-1}$, $\mu = 0.333h^{-1}$, $LR_{target} = 7$. The 'ideal' concentration profile consists of the concentration $c_{opt} = 0.17 \frac{mg}{L}$ for a time duration $T_{opt} = 33.0h$, while the optimal bolus+continuous dosing schedule provides a bolus dose of size $c_{opt} \cdot V = 0.17 \cdot Vmg$ (where V is the volume of distribution), followed by a continuous infusion of $c_{opt} \cdot \mu \cdot V = 0.056 \cdot V \frac{mg}{h}$ up to time $T_{bc,opt} = 31.3h$.

degree to which a proposed intermittent schedule can be improved upon by increasing the frequency of dosing or by shifting to continuous infusion. To illustrate this, we have taken the optimal bolus+continuous schedule presented in Figure 4, and generated an intermittent dosing schedule which approximates it, with bolus doses given at 6-hour intervals. The maintenance doses are equal to the total doses given by the optimal bolus+continuous schedule over 6 hours, while to obtain the loading dose we add the loading dose for the bolus+continuous schedule to the above maintenance dose. The resulting dosing schedule, whose outcomes are presented in Figure 5 (top) achieves the target $B(t) = 10^{-7}B_0$ after 36.0 hours, compared with 34.8 hours for the optimal bolus+continuous schedule with $AUC = 6.61 \frac{\dot{mg} \cdot h}{L}$, only 14% higher than the AUC corresponding to optimal bolus+continuous schedule and %18 higher than the 'ideal' value AUC_{opt} . This demonstrates that it is possible to use the results obtained here to generate intermittent schedules which achieve outcomes quite close to the theoretical ideal. However, if the interval between doses becomes larger, the performance of the intermittent approximation to the optimal bolus+continuous schedule degrades. In the bottom part of Figure 5 we used the same procedure to generate a schedule with 12-hours intervals. This schedule achieves the target at time t = 43.4 hours, and its AUC is $8.64 \frac{mg \cdot h}{L}$, 48% higher than the 'ideal' AUC_{opt} .

7 Discussion

The results obtained in this work provide a baseline and a reference point for evaluating the efficient use of antimicrobials. Theorem 1 describes the 'ideal' concentration profile leading to eradication of the microbial population, with a minimal AUC - which



Fig. 5 Outcomes of a intermittent dosing schedules approximating the optimal bolus+continuous schedule presented in Figure 4 (antimicrobial concentration C(t) $\left(\frac{mg}{L}\right)$ at time t (hours) on the left, microbial population on the right). Parameters are identical to those in Figure 4 (corresponding to the example from Bouvier d'Yvoire and Maire (1996) of Tobramycin applied to *Pseudomonas aeruginosa*). The dosing schedule are: Top: a loading dose of size $0.51 \cdot Vmg$ (where V is the volume of distribution) and 5 bolus maintenance doses of size $0.34 \cdot Vmg$, given at 6h intervals. Bottom: a loading dose of size $0.68 \cdot Vmg$, given at 12h intervals.

consists of a constant concentration c_{opt} applied over a period of duration T_{opt} . We provided simple equations allowing to compute the key quantities c_{opt} and T_{opt} for an arbitrary pharmacodynamic function k(c), and explicit expressions for these quantities in the case of the widely-used Hill-type function (see (4.1),(4.2)).

Since the 'ideal' concentration profile is not strictly feasible due to pharmacokinetic contraints, we have also considered the question of determining an optimal bolus+continuous dosing schedule, assuming first order pharmacokinetics. Our results show that the optimal dosing leads to the *same* constant concentration c_{opt} as for the 'ideal' concentration profile during a dosing period $T_{bc,opt} < T_{opt}$. Our numerical comparisons show that the results obtained using this optimal bolus+continuous dosing plan are in most cases only slightly inferior to those obtained using the 'ideal' concentration profile.

We note that while the 'ideal' concentration profile was proved to be optimal among *all* concentration profiles (Theorem 1), in the investigation of dosing plans under pharmacokinetic constraints we restricted ourselves in advance to bolus+continuous plans with constant dosing rate following the loading dose. In fact we conjecture that no dosing schedule with a non-constant dosing rate can improve upon the performance of the dosing plans considered, but leave a full treatment of this question to future work.

The models which we employed in this study are standard ones, which are widely applied in the quantitative literature on antimicrobial pharmacology. However, as always with mathematical modelling, it is important to take into account the limitations of the model employed, and their possible implications regarding the conclusions drawn using the model. In particular, since a central feature of the 'ideal' concentration profile, as presented in Theorem 1, is that it consists of a *constant* concentration provided over a finite duration of time, one should investigate whether additional mechanisms, not taken into account by the model, might modify this conclusion. Are there mechanisms whose inclusion in the model would entail that the 'ideal' concentration profile will be time-varying, and if so in what way? Could an intermittent dosing schedule be optimal under some circumstances? Below we mention several relevant mechanisms, which have been included in some models of antimicrobial pharmacodynamics, and whose implications for the optimization of dosing schedules merit systematic study.

(1) Density-dependence of microbial population growth. This will be relevant if, before treatment begins, the microbial population reaches a size which is close to the environmental carrying capacity, so that resource limitation leads to significant reduction of the growth rate. Several published models have included this mechanism, either by replacing the constant per capita growth term in (2.3) by a nonlinear (typically logistic) term (Bhagunde et al. (2015), Geli et al. (2012), Kesisoglou et al. (2022), Nikolaou and Tam (2006), Paterson et al. (2016), Tindall et al. (2022)), or by explicitly modelling the resource dynamics (Ali et al. (2022), Khan and Imran (2018), Levin and Udekwu (2010), Zilonova et al. (2016)). We expect that when density-dependent growth is included in the model, the 'ideal' concentration profile (the solution of Problem 1) will no longer be constant in time. However, some simulations we have carried out (not shown) indicate that practical implications of this fact are not necessarily large: as soon as the microbial population is reduced, by the antimicrobial action, so that it is not close to the carrying capacity, the linear model as in (2.3) becomes a good approximation, hence the associated 'ideal' concentration profile (3.1) is nearly optimal. This issue should be systematically explored in future work.

(2) Immune response. When the strength of immune supression of microbial growth is comparable to that of the antimicrobial effect, it should be taken into consideration when modelling the microbial dynamics. In some cases immune response is modelled as a killing term of microbes with a constant per capita rate, which is equivalent to reducing the growth-rate parameter r in (2.3), hence does not induce a change in the model structure (Goranova et al. (2022)). However, in some studies the immune reponse is modelled as depending nonlinearly on the bacterial population size (Hoyle

et al. (2020)) or as an explicit time-varying component representing the gradual buildup of immune response (Geli et al. (2012), Tindall et al. (2022)). Implications of such a change to model structure with respect to the optimal design of treatment require study.

(3) Persister cells. One mechanism which can allow some bacterial species to survive antibiotics is phenotypic switching of cells from an antibiotic-sensitive state to a persister state with greatly reduced sensitivity to the antibiotic, and for which growth rate is also reduced (Brauner et al. (2016)). The small population of persistent cells is therefore at a competitive disadvantage under antibiotic-free conditions, but in the presence of antibiotic it allows the bacterial population to survive. Theorerical studies of antimicrobial treatment of microbial populations including persisters (Cogan (2006), Cogan et al. (2012)) show that, when the transition of microbes from the persistent state back to the sensitive state does not occur in the presence of the antimicrobial, the microbial population cannot be eliminated by a constant application of antimicrobial, and elimination requires a series of applications of the antimicrobial, separated by withdrawl periods. The optimal antibacterial treatment schedules in the presence of persisters will thus of necessity be quite different from those presented in this work.

(4) Antimicrobial resistance. This refers to clones of microbial cells which are insestive to antimicrobial action. The effort to prevent antimicrobial resistance is an important motivation for the efficient use of antimicrobial agents, which has been studied here. However the model we employed does not directly address this issue, as do models which include a separate compartment for resistant strains which may arise due to mutations (Ali et al. (2022), Geli et al. (2012), Goranova et al. (2022), Khan and Imran (2018), Lipsitch and Levin (1997), Marrec and Bitbol (2020), Morsky and Vural (2022), Nielsen and Friberg (2013), Paterson et al. (2016), Singh et al. (2023), Zilonova et al. (2016)). This can lead to additional considerations regarding optimization of antimicrobial use.

We thus conclude that it is important to examine whether, how, and to what extent the incorporation of additional mechanisms into the models modifies the conclusions obtained here. The analytical results presented here should form a useful point of reference for comparison with results obtained using modified and extended models.

It is relevant to mention here the extensive literature on the modelling and optimization of chemotherapeutic treatment in oncology (see Shi et al. (2014) for an overview), noting that some of the basic models employed in that field have a structure similar to those used in the study of antimicrobial treatment, with microbial population size replaced by tumor size. In particular, the recent works Leszczyński et al. (2020), Ledzewicz and Schättler (2021) treat optimization problems which are closely related to those considered here, for a more general model including nonlinear growth, both in a purely pharmacodynamic version and in the case that pharamcokinetics is taken into account. These works derived first-order optimalilty conditions using the Pontryagin maximum principle, and used these conditions to obtain information on the structure of optimal solutions, though they did not present explicit and detailed results for the case of linear growth, as obtained here. We note that in the present work we did not use variational tools such as the maximum principle, and our proof of the (global) optimality of the 'ideal' concentration profile (Theorem 1) is direct and elementary.

Finally, we remark that our analyses assume known pharmacodynamic and pharmacokinetic parameters, but these parameters themselves will vary among individuals, and the design of treatment plans must also take into account this heterogeneity, a fact which has led to the development of population PK/PD modelling (de Velde at al. (2018), Vinks et al. (2014)). Incorporating the insights obtained from the results in the present work into the population perspective remains a task for future research.

References

- Ali, A, Imran, M, Sial, S, Khan, A (2022) Effective antimicrobial dosing in the presence of resistant strains. PLoS ONE 17:e0275762. https://doi.org/10.1371/journal.pone.0275762
- Austin, DJ, White, NJ, Anderson, RM (1998) The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J. Theor. Biol. 194:313-339. https://doi.org/10.1006/jtbi.1997.0438
- Bhagunde, PR, Nikolaou, M, Tam, VH (2015) Modeling heterogeneous bacterial populations exposed to antibiotics: The logistic dynamics case. AIChE J. 61:2385-2393. https://doi.org/10.1002/aic.14882
- Bouvier d'Yvoire, MJ, Maire, PH (1996) Dosage regimens of antibacterials. Clin. Drug Invest. 11:229-239. https://doi.org/10.2165/00044011-199611040-00006
- Brauner, A, Fridman, O, Gefen, O, Balaban, NQ (2016) Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat. Rev. Microbiol., 14:320-330.
- Bulitta, JB, Hope, WW, Eakin, AE, Guina, T., Tam, VH, Louie, A, Drusano, GL, Hoover, JL (2019) Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans. Antimicrob. Agents Chemother. 63:e02307-18. https://doi.org/10.1128/AAC.02307-18
- Cicchese, JM, Pienaar, E, Kirschner, DE, Linderman, JJ (2017) Applying optimization algorithms to tuberculosis antibiotic treatment regimens. Cell. Mol. Bioeng. 10:523-535. https://doi.org/10.1007/s12195-017-0507-6
- Cogan, NG (2006) Effects of persister formation on bacterial response to dosing. J. Theor. Biol. 238:694-703. https://doi.org/10.1016/j.jtbi.2005.06.017

- Cogan, NG, Brown, J, Darres, K, Petty, K (2012) Optimal control strategies for disinfection of bacterial populations with persister and susceptible dynamics. Antimicrob. Agents Chemother. 56:4816-4826. https://doi.org/10.1128/aac.00675-12
- Colin, PJ, Eleveld, DJ, & Thomson, AH (2020) Genetic Algorithms as a Tool for Dosing Guideline Optimization: Application to Intermittent Infusion Dosing for Vancomycin in Adults. CPT: Pharmacometrics Syst. Pharmacol. 9:294-302. https://doi.org/10.1002/psp4.12512
- Corvaisier, S, Maire, PH, Bouvier d'Yvoire, MY, Barbaut, X, Bleyzac, N, Jelliffe, RW (1998) Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob. Agents Chemother. 42:1731-1737. https://doi.org/10.1128/AAC.42.7.1731
- Czock, D, & Keller, F (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J. Pharmacokinet. Pharmacodyn. 34:727-751. https://doi.org/10.1007/s10928-007-9069-x
- Derendorf, H, Schmidt, S (2019) Rowland and Tozer's clinical pharmacokinetics and pharmacodynamics: concepts and applications, Wolters Kluwer, South Holland.
- de Velde, F, Mouton, JW, de Winter, BC, van Gelder, T, Koch, BC (2018) Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. Pharmacol. Res. 134:280-288. https://doi.org/10.1016/j.phrs.2018.07.005
- Geli, P, Laxminarayan, R, Dunne, M, Smith, DL (2012) "One-size-fits-all"? Optimizing treatment duration for bacterial infections. PloS ONE 7:e29838. https://doi.org/10.1371/journal.pone.0029838
- Goranova, M, Ochoa, G, Maier, P, Hoyle, A (2022) Evolutionary optimisation of antimicrobial dosing regimens for bacteria with different levels of resistance. Artificial Artif. Intell. Med. 133:102405. https://doi.org/10.1016/j.artmed.2022.102405
- Hoyle, A, Cairns, D, Paterson, I, McMillan, S, Ochoa, G, Desbois, AP (2020) Optimising efficacy of antimicrobials against systemic infection by varying dosage quantities and times. PLoS Comput. Biol. 16:e1008037. https://doi.org/10.1371/journal.pcbi.1008037
- Kesisoglou, I, Tam, VH, Tomaras, AP, Nikolaou, M (2022) Discerning in vitro pharmacodynamics from OD measurements: A model-based approach. Comput. Chem. Eng. 158:107617. https://doi.org/10.1016/j.compchemeng.2021.107617
- Khan, A, Imran, M (2018) Optimal dosing strategies against susceptible and resistant bacteria. J. Biol. Syst. 26:41-58. https://doi.org/10.1142/S0218339018500031

- Krzyzanski, W, Jusko, WJ (1998). Integrated functions for four basic models of indirect pharmacodynamic response. J. Pharm. Sci. 87:67-72. https://doi.org/10.1021/js970168r
- Ledzewicz, U, Schättler, H (2021) On the role of pharmacometrics in mathematical models for cancer treatments. Discrete Continuous Dyn Syst Ser B 26:483-499. https://doi.org/10.3934/dcdsb.2020213
- Leszczyński, M, Ledzewicz, U, Schättler, H (2020) Optimal control for a mathematical model for chemotherapy with pharmacometrics. Math. Modell. Nat. Phenom. 15:69. https://doi.org/10.1051/mmnp/2020008
- Levin, BR, Udekwu, KI (2010) Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuousculture experiments. Antimicrob. Agents Chemother. 54:3414-3426. https://doi.org/10.1128/AAC.00381-10
- Lipsitch, M, Levin, BR (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41: 363-373. https://doi.org/10.1128/AAC.41.2.363
- Luterbach, CL, Rao, GG (2022) Use of pharmacokinetic/pharmacodynamic approaches for dose optimization: a case study of plazomicin. Curr. Opin. Microbiol. 70:102204. https://doi.org/10.1016/j.mib.2022.102204
- Macheras, P, Iliadis, A (2016) Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: homogeneous and heterogeneous approaches, Springer, Heidelberg.
- Marrec, L, Bitbol, AF (2020) Resist or perish: fate of a microbial population subjected to a periodic presence of antimicrobial. PLoS Comput. Biol. 16:e1007798. https://doi.org/10.1371/journal.pcbi.1007798
- Meibohm, B, Derendorf, H (1997) Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int. J. Clin. Pharmacol. Ther. 35:401-413.
- Mi, K, Zhou, K, Sun, L, Hou, Y, Ma, W, Xu, X, Huo, M, Liu, Z, Huang, L. (2022) Application of Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Model in Antimicrobial Resistance. Pharmaceutics 14,246. https://doi.org/10.3390/pharmaceutics14020246
- Morsky, B, Vural, DC (2022) Suppressing evolution of antibiotic resistance through environmental switching. Theor. Ecol. 15:115-127. https://doi.org/10.1007/s12080-022-00530-4

- Mouton, JW, Vinks, AS (2005) Pharmacokinetic/Pharmacodynamic modelling of antibiotics in vitro and in vivo using bacterial growth and kill kinetics: the zMIC vs stationary concentrations. Clin. Pharmacokinet. 44: 201-10. https://doi.org/10.2165/00003088-200544020-00005
- Mudassar, I, Smith, H (2005) The pharmacodynamics of antibiotic treatment. Comput. Math. Methods. Med., 7:229-263. https://doi.org/10.1080/10273660601122773
- Mueller, M, de la Pena, A, Derendorf, H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48:369-377. https://doi.org/10.1128/AAC.48.2.369-377.2004
- Murray, CJ, Ikuta, KS, Sharara, F, et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399:629-655. https://doi.org/10.1016/S0140-6736(21)02724-0
- Nguyen, HM, Peletier, LA (2009), Monotonicity of time to peak response with respect to drug dose for turnover models, Diff. Int. Eq. 22:1-26.
- Nielsen, EI, Friberg, LE (2013) Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol. Rev. 65:1053-1090. https://doi.org/10.1124/pr.111.005769
- Nikolaou, M, Tam, VH (2006) A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations. J. Math. Biol. 52:154-182. https://doi.org/10.1007/s00285-005-0350-6
- Nikolaou, M, Schilling, AN, Vo, G, Chang, KT, Tam, VH (2007) Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents. Ann. Biomed. Eng. 35:1458-1470. https://doi.org/10.1007/s10439-007-9306-x
- Onufrak, NJ, Forrest, A, Gonzalez, D (2016) Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. Clin. Ther. 38:1930-1947. https://doi.org/10.1016/j.clinthera.2016.06.015
- Owens, RC, Nightingale, CH, Ambrose, PG (Eds.) (2004) Antibiotic optimization: concepts and strategies in clinical practice. Marcel Dekker, New York.
- Paterson, IK, Hoyle, A, Ochoa, G, Baker-Austin, C, Taylor, NG (2016) Optimising antimicrobial usage to treat bacterial infections. Sci. Rep. 6:1-10. https://doi.org/10.1038/srep37853
- Peletier, LA, Gabrielsson, J, Haag, JD (2005). A dynamical systems analysis of the indirect response model with special emphasis on time to peak response. J. Pharmacokinet. Pharmacodyn. 32:607-654. https://doi.org/10.1007/s10928-005-0047-x

- Peña-Miller, R, Lähnemann, D, Schulenburg, H, Ackermann, M, & Beardmore, R (2012) Selecting against antibiotic-resistant pathogens: optimal treatments in the presence of commensal bacteria. Bull. Math. Biol. 74:908-934. https://doi.org/10.1007/s11538-011-9698-5
- Rayner, CR, Smith, PF et. al. (2021) Model informed drug development for anti?infectives: state of the art and future. Clin. Pharmacol. Ther. 109:867-891. https://doi.org/10.1002/cpt.2198
- Rao, GG, Landersdorfer, CB (2021) Antibiotic pharmacokinetic/pharmacodynamic modelling: zMIC, pharmacodynamic indices and beyond. Int. J. Antimicrob. Agents 58:106368. https://doi.org/10.1016/j.ijantimicag.2021.106368
- Regoes, RR, Wiuff, C, Zappala, RM, Garner, KN, Baquero, F., & Levin, B.R. (2004) Pharmacodynamic functions: a multiparameter approach to the design of antimicrobial treatment regimens. Antimicrob. Agents Chemother. 48:3670-3676. https://doi.org/10.1128/AAC.48.10.3670-3676.2004
- Rescigno, A. (2003) Foundations of Pharmacokinetics. Springer, New York.
- Rotschafer, JC, Andes, DR, Rodvold, KA (Eds.) (2016) Antibiotic Pharmacodynamics. Springer, New York.
- Shi, J, Alagoz, O, Erenay, FS, Su, Q (2014) A survey of optimization models on cancer chemotherapy treatment planning. Ann. Oper. Res. 221:331-356. https://doi.org/10.1007/s10479-011-0869-4
- Singh, G, Orman, MA, Conrad, JC, Nikolaou, M. (2023) Systematic design of pulse dosing to eradicate persister bacteria. PLoS Comput. Biol. 19:e1010243. https://doi.org/10.1371/journal.pcbi.1010243
- Smith, NM, Lenhard, JR et. al. (2020) Using machine learning to optimize antimicrobial combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii. Clin. Microbiol Infecti. 26:1207-1213. https://doi.org/10.1016/j.cmi.2020.02.004
- Tindall, M, Chappell, MJ, Yates, JW (2022) The ingredients for an antimicrobial mathematical modelling broth. Int. J. Antimicrob. Agents 60:106641. https://doi.org/10.1016/j.ijantimicag.2022.106641
- Ventola, CL (2015) The antibiotic resistance crisis: part 1: causes and threats. Pharm. Ther. 40:277.
- Vinks, AA, Derendorf, H, Mouton, JW (Eds.) (2014) Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. Springer, New York.

- Wen, X, Gehring, R, Stallbaumer, A, Riviere, JE, Volkova, V. V. (2016) Limitations of zMIC as sole metric of pharmacodynamic response across the range of antimicrobial susceptibilities within a single bacterial species. Sci. Rep. 6:1-8. https://doi.org/10.1038/srep37907
- Wu, X, Zhang, H, Li, J (2022). An Analytical Approach of One-Compartmental Pharmacokinetic Models with Sigmoidal Hill Elimination. Bull. Math. Biol., 84:117. https://doi.org/10.1007/s11538-022-01078-4
- Zhi, J, Nightingale, CH, Quintiliani, R (1988) Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J. pharmacokinetic. biopharm. 16:355-375. https://doi.org/10.1007/BF01062551
- Zilonova, EM, (2016)Optimal strategies antibi-Bratus, ASinotic treatment of microbial populations. Appl. Anal., 95:1534-1547. https://doi.org/10.1080/00036811.2016.1143552